FTSE 100 news / Companies and sectors / GSK / FDA approves GSK's Hibsago for chronic hepatitis B
FDA approves GSK's Hibsago for chronic hepatitis B
+10.0 strongly positive
The FDA approved GSK's bepirovirsen (Hibsago) for chronic hepatitis B.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| GSK US | 1 | +10.0 |
| Reuters | 1 | +10.0 |
| FirstWord Pharma | 1 | +10.0 |
| Investing.com India | 1 | +10.0 |
| TradingView | 1 | +10.0 |
| Seeking Alpha | 1 | +10.0 |
| NewsBytes | 1 | +10.0 |
| TipRanks | 1 | +10.0 |
| GenomeWeb | 1 | +10.0 |
Day by day
Wednesday 21 October 2026
The FDA approved GSK's bepirovirsen (Hibsago) for chronic hepatitis B.
- +10.0 Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)
Company announces US approval of Hibsago - +10.0 US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Reuters reports approval allowing patients to stop treatment - +10.0 FDA approves GSK's ASO as functional cure for hepatitis B
Approval described as functional cure for hepatitis B - +10.0 FDA approves GSK’s Hibsago for chronic hepatitis B treatment By Investing.com
FDA approval of Hibsago for chronic hepatitis B is major positive - +10.0 GSK Says US FDA Approves Hibsago For Chronic Hepatitis B
Same FDA approval of Hibsago, strongly positive - +10.0 GSK wins approval of bepirovirsen for hepatitis B (GSK:NYSE)
Approval of bepirovirsen for hepatitis B - +10.0 FDA approves GSK's Hibsago for sustained control of hepatitis B
FDA approval for hepatitis B drug, positive - +10.0 GSK’s Hibsago approved by FDA for treatment of CHB
FDA approval of Hibsago for chronic hepatitis B - +10.0 FDA Greenlights GSK’s Chronic HBV Antisense Oligo With Roche CDx Test
FDA approval alongside companion diagnostic test